Last reviewed · How we verify
NCT03395925
Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid
NA trial testing Celon Pro Surge in Thyroid Nodule. Withdrawn.
30 October 2021
Quick facts
| Lead sponsor | Olympus Surgical Technologies Europe |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 10 November 2017 |
| Primary completion | 30 October 2021 |
| Estimated completion | 30 January 2022 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Celon Pro Surge
Conditions studied
- Thyroid Nodule — all drugs for Thyroid Nodule →
Sponsor
Olympus Surgical Technologies Europe
Who can join
18 and older, any sex, with Thyroid Nodule. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Thyroid nodules are among the common alterations of the thyroid. Depending on the detection method the prevalence is between 20% and 50%, whereas the incidence increases with improvement of ultrasonic technology. The CelonPro Surge bipolar coagulation electrode operated with the compatible power control unit and compatible tube pump is indicated for ablation and coagulation of soft tissue, including thermal inactivation and/or volume reduction of locally defined tissue areas, such as tumors and metastases. The primary objective of the study is to assess the influence of radiofrequency ablation due to thyroid volume after 24 hours, 3 months, 6 months and 1 year.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03395925
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Nodule
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07488325 — Multimodal Assessment of Malignancy in Atypia of Undetermined Significance in Thyroid Nodules Using Ultrasound and Cytol · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07287176 — Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System · NA · recruiting
- NCT06730321 — Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment · recruiting
Other Olympus Surgical Technologies Europe trials
Trials by the same sponsor.
- NCT04398420 — Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03395925 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Olympus Surgical Technologies Europe
- Last refreshed: 23 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03395925.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing